Clinical trials: Obese With Comorbidities
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2…
- Trial name
- SURMOUNT-5 (NCT05822830)
- Testing
- Tirzepatide, Semaglutide
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 751 people
- Sponsor
- Eli Lilly and Company
Obesity
Interdisciplinary Weight Loss Therapy Associate With the Use of Interactive Digital Technology
Obesity is a complex disease associate to metabolic alterations, which may lead to cardiometabolic risk in women with obesity. The use of interactive digital technology as adjuvante tool to the clinical practices in weight loss…
- Trial name
- NCT04034472
- Testing
- Interdisciplinary intervention in obesity
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Federal University of São Paulo
Obesity
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities.
- Trial name
- NCT00386061
- Testing
- rimonabant (SR141716)
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 1,507 people
- Sponsor
- Sanofi
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Overweight or Obesity
- Trial name
- ATTAIN-1 (NCT05869903)
- Testing
- Orforglipron
- Where
- 138 sites in United States, Brazil and 8 more
- Volunteers
- 3,127 people
- Sponsor
- Eli Lilly and Company
Obesity
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
- Trial name
- ZUPREME (NCT06662539)
- Testing
- Petrelintide
- Where
- 32 sites in United States, Poland and 1 more
- Volunteers
- 493 people
- Sponsor
- Zealand Pharma
Obesity, Hypertension
Physical Activity, Functional Capacity and Quality of Life in Older Patients With Chronic Comorbidities
The prevalence of obesity, hypertension (HT) and type 2 diabetes (T2D) is increasing. The adoption of an increasingly sedentary lifestyle is one of the main factors contributing to the increased incidence of chronic diseases such…
- Conditions
- Obesity, Hypertension, Type 2 Diabetes
- Trial name
- NCT06535295
- Where
- Turkey (Türkiye)
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Biruni University
Psoriasis
Effect of Weight Loss on Psoriasis
Controlled data show that obesity is a risk factor for psoriasis and that psoriasis severity is correlated with the degree of overweight.
- Trial name
- NCT01137188
- Testing
- Low calorie diet
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- AURORA-1 (NCT07743463)
- Testing
- ASC30 tablets A1
- Where
- 122 sites in United States, Canada and 5 more
- Volunteers
- 3,003 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity or Overweight
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for…
- Trial name
- ASCEND (NCT06862791)
- Testing
- AZD9550, AZD6234
- Where
- 53 sites in United States, Australia and 3 more
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Depression, Depressive Disorder
Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy.
- Conditions
- Depression, Depressive Disorder, Overweight or Obesity, Depressive Symptoms
- Trial name
- NCT07654179
- Testing
- Metformin, Antidepressant Therapy
- Where
- 2 sites in Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Obesity or Overweight
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults…
- Trial name
- COMO-1 (NCT06867718)
- Testing
- RGT001-075
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Regor Pharmaceuticals Inc.
Mild Cognitive Impairment, Obesity
Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition
Obesity has been associated with cognitive impairments, lower blood flow, metabolic activity and brain volume. Obesity in adulthood is a risk factor for Alzheimer's disease in the elderly.
- Trial name
- NCT01286389
- Testing
- medical care, caloric restriction
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo General Hospital
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
- Trial name
- NCT06047548
- Testing
- Tirzepatide
- Where
- 20 sites in United States
- Volunteers
- 441 people
- Sponsor
- Eli Lilly and Company
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight.
- Trial name
- NCT07255209
- Testing
- IBI362
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
- Trial name
- NCT06277934
- Testing
- RGT001-075
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Regor Pharmaceuticals Inc.
Obesity & Overweight
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or…
- Trial name
- NCT07652047
- Testing
- CX11
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Corxel Pharmaceuticals
Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities
The goal of this randomized, double-blind, placebo-controlled, phase IIa study is to demonstrate superiority on body weight reduction of two different doses of twice daily distal jejunal-release dextrose beads formulations (APHD…
- Trial name
- NCT07008456
- Testing
- APHD-012, APHD-002, APHP-012
- Where
- 6 sites in Georgia
- Volunteers
- 102 people
- Sponsor
- Aphaia Pharma US LLC
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- AZD6234
- Where
- 212 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca